Cellosaurus cell line NK-92 (CVCL_2142) (original) (raw)

Publications

PubMed=8152260
Jian-Hong Gong, Guitta Maki, Hans-Georg Klingemann;
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia 8:652-658(1994)

PubMed=9118301
Hans-Georg Klingemann, Elaine Wong, Guitta Maki;
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=9573023; DOI=10.1182/blood.V91.10.3850
Shigeki Nagashima, Robbie Mailliard, Yoshiro Kashii, Torsten E. Reichert, Ronald Bruce Herberman, Paul Robbins, Theresa L. Whiteside;
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Blood 91:3850-3861(1998)

PubMed=10365666; DOI=10.1089/10430349950018030
Ying K. Tam, Guitta Maki, Blythe Miyagawa, Burkhard Hennemann, Torsten Tonn, Hans-Georg Klingemann;
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Hans Gunther Drexler, Yoshinobu Matsuo;
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Hans Gunther Drexler;
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11454312; DOI=10.1089/152581601750288975
Guitta Maki, Hans-Georg Klingemann, Jeffrey A. Martinson, Ying K. Tam;
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523
Ying K. Tam, Jeffrey A. Martinson, K. Doligosa, Hans-Georg Klingemann;
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Cytotherapy 5:259-272(2003)

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954
Angen Liu, Tetsuya Takakuwa, Wen-Juan Luo, Shigeki Fujita, Katsuyuki Aozasa;
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Cancer Sci. 97:605-610(2006)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560
Liat Binyamin, R. Katherine Alpaugh, Tracey L. Hughes, Charles T. Lutz, Kerry S. Campbell, Louis M. Weiner;
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3
Javeed Iqbal, Can Kucuk, Ronald J. Deleeuw, Gopesh Srivastava, Wayne Tam, Hui-Min Geng, David L. Klinkebiel, Judith K. Christman, Kavita N. Patel, Ka-Jia Cao, Li-Jun Shen, Karen Dybkaer, Ivy F.L. Tsui, Hesham H. Ali, Norio Shimizu, Wing Yan Au, Wan L. Lam, Wing-Chung Chan; Show fewer authors
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Cord C. Uphoff, Sabine A. Denkmann, Klaus G. Steube, Hans Gunther Drexler;
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Javeed Iqbal, Dennis D. Weisenburger, Aparajita Chowdhury, Ming-Ying Tsai, Gopesh Srivastava, Timothy Charles Greiner, Can Kucuk, Karen E. Deffenbacher, Julie Marie Vose, Lynette Smith, Wing Yan Au ...Show all 22 authors... , Shigeo Nakamura, Masao Seto, Jan Delabie, Francoise Berger, Florence Loong, Young-Hyeh Ko, Ivy Sng, Xin Liu, Thomas P. Loughran Jr., James Olen Armitage, Wing-Chung Chan; Show fewer authors
International Peripheral T-cell Lymphoma Project
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010
Alfred Schnueriger, Roger Grau, Peter Sondermann, Thomas Schreitmueller, Stefan Marti, Marcel Zocher;
Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911
Can Kucuk, Bei Jiang, Xiao-Zhou Hu, Wen-Yan Zhang, John K.C. Chan, Wen-Ming Xiao, Nathan Lack, Can Alkan, John C. Williams, Kendra N. Avery, Pynar Kavak ...Show all 28 authors... , Anna Scuto, Emel Sen, Philippe Gaulard, Louis Michael Staudt, Javeed Iqbal, Wei-Wei Zhang, Adam Cornish, Qiang Gong, Qun-Pei Yang, Hong Sun, Francesco Annibale d'Amore, Sirpa Leppa, Wei-Ping Liu, Kai Fu, Laurence de Leval, Timothy W. McKeithan, Wing-Chung Chan; Show fewer authors
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025.1-6025.12(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582
Garnet Suck, Marcus Odendahl, Paulina Nowakowska, Christian Seidl, Winfried S. Wels, Hans-Georg Klingemann, Torsten Tonn;
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623
Justin Tyme Gunesch, Laura S. Angelo, Sanjana Mahapatra, Raquel Payzant Deering, Johanna E. Kowalko, Patrick Sleiman, John W. Tobias, Linda Monaco-Shawver, Jordan Scott Orange, Emily M. Mace;
Genome-wide analyses and functional profiling of human NK cell lines.
Mol. Immunol. 115:64-75(2019)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912
Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, Injung Hwang, Hyun Tak Jin, Young Chul Sung, Ki-Seong Eom, Sae Won Kim;
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
J. Immunother. Cancer 7:138.1-138.17(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Hilmar Quentmeier, Claudia Pommerenke, Wilhelm Gerhard Dirks, Sonja Eberth, Max Koeppel, Roderick A.F. MacLeod, Stefan Nagel, Klaus G. Steube, Cord C. Uphoff, Hans Gunther Drexler;
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218.1-8218.14(2019)

PubMed=34349345; DOI=10.1007/s10616-021-00476-1; PMCID=PMC8319282
Hui Zhao, Zhen-Long Zhou, Guang-Meng Li, Gang Liu, Shu-Yin Lin, Wei Chen, Sheng Xiong;
An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Cytotechnology 73:539-553(2021)

PubMed=36610812; DOI=10.1016/j.jcyt.2022.12.003
Hans-Georg Klingemann;
The NK-92 cell line -- 30 years later: its impact on natural killer cell research and treatment of cancer.
Cytotherapy 25:451-457(2023)